Diabetomics
Hillsboro, US · 1 known investors
ModalityDx develops quantitative point-of-care diagnostic tests using molecular biomarkers and data science to detect and assess treatment response for diseases including diabetes, maternal health conditions, and autoimmune disorders. The company also supports pharmaceutical firms in drug development and therapeutic efficacy assessment.
Founders & leadership
DG
Dave GundersonNamed on SEC filing
RM
Rick MillerNamed on SEC filing
CD
Chris DudleyNamed on SEC filing
RG
Robert GreggNamed on SEC filing
RG
Robert GooteeNamed on SEC filing
SR
Srinivasa Rao NagallaNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2014
▶$2.5MraisedNov 2014 · 1 investors · Other Health CareRule 506(b)
▶$2.5MraisedNov 2014 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Dave GundersonExecutive Officer, Director
- Rick MillerDirector
- Chris DudleyDirector
- Robert GreggDirector
- Robert GooteeDirector
- Srinivasa Rao NagallaExecutive Officer, Director, Promoter
- Offering amount
- $15M
- Amount sold
- $2.5M
- First sale
- Oct 2014
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Diabetomics do?
- ModalityDx develops quantitative point-of-care diagnostic tests using molecular biomarkers and data science to detect and assess treatment response for diseases including diabetes, maternal health conditions, and autoimmune disorders. The company also supports pharmaceutical firms in drug development and therapeutic efficacy assessment.
- Who are Diabetomics's investors?
- Diabetomics's investors include VenturEast.
- How much funding has Diabetomics raised?
- Diabetomics has disclosed $2.5M raised across 1 round.
- Where is Diabetomics headquartered?
- Diabetomics is headquartered in Hillsboro, US.